Classifications: quinolone antibiotic;
Therapeutic: antibiotic

Prototype: Ciprofloxacin
Pregnancy Category: C


400 mg tablets


An oral fluoroquinolone broad spectrum bactericidal agent that inhibits DNA gyrase, an enzyme necessary for bacterial DNA replication and some aspects of its transcription, repair, recombination, and transposition.

Therapeutic Effect

Inhibits replication of susceptible gram-negative and gram-positive bacteria. Antibiotic spectrum of activity is similar to that of other fluoroquinolones.


Urinary tract infections, transurethral surgery prophylaxis.

Unlabeled Uses

Lower respiratory tract infections.


Known hypersensitivity to lomefloxacin or any other quinolone; tendon pain; QT prolongation; renal failure or Clcr <10 mL/min; pregnancy (category C), lactation.

Cautious Use

Kidney disease; acute MI, atrial fibrillation, bradycardia; cerebrovascular disease; myasthenia gravis; patients with a history of epilepsy, psychosis, or increased intracranial pressure; children and adolescents.

Route & Dosage

Urinary Tract & Lower Respiratory Tract Infections
Adult: PO 400 mg q.d. x 10 d

Transurethral Surgery Prophylaxis
Adult: PO 400 mg 2–6 h before surgery


  • Avoid giving mineral supplements or vitamins with iron or zinc within 2 h of lomefloxacin.
  • Do not give antacids with magnesium, aluminum, or sucralfate within 4 h before or 2 h after drug.
  • Give hemodialysis patients an initial 400 mg loading dose followed by a 200 mg/d maintenance dose.

Adverse Effects (≥1%)

CNS: Headache, peripheral neuropathy. GI: Nausea, abdominal discomfort. Skin: Photosensitivity. Musculoskeletal: Risk of tendon rupture (rare).

Diagnostic Test Interference

May cause false positive on opiate screening tests.


Drug: aluminum- and magnesium-containing antacids decrease systemic bioavailability of lomefloxacin. Concurrent corticosteroid use may increase the risk of tendon rupture.


Absorption: Readily from GI tract. Peak: 1–2 h. Distribution: Crosses placenta; distributed into breast milk. Elimination: 76% in urine within 48 h. Half-Life: 6.35–7.77 h.

Nursing Implications

Assessment & Drug Effects

  • Lab tests: Draw C&S prior to first dose; drug may be started pending results of C&S.
  • Take thorough history of hypersensitivity reactions to quinolones or other drugs prior to therapy.
  • Discontinue lomefloxacin and notify physician at the first sign of a skin rash or other allergic reaction.
  • Monitor for tendon pain. If it occurs, hold the drug and report to physician.
  • Monitor for seizures, especially in patients with known or suspected CNS disorders. Discontinue lomefloxacin and notify physician immediately if a seizure occurs.
  • Assess for S&S of superinfection (see Appendix F).

Patient & Family Education

  • Notify physician of loose stools or diarrhea promptly.
  • Drink fluids liberally, if not contraindicated.
  • Take appropriate cautions, dizziness or light-headedness may occur.
  • Be aware of the possibility of phototoxicity; avoid excessive sunlight or artificial ultraviolet light.

Common adverse effects in italic, life-threatening effects underlined; generic names in bold; classifications in SMALL CAPS; Canadian drug name; Prototype drug

© 2006-2022 medpill.info Last Updated On: 11/17/2022 (0)
Wait 20 seconds...!!!